Lung cancer is one of the most aggressive tumour types. Targeted therapies stratified by
oncogenic drivers have substantially improved therapeutic outcomes in patients with non-small-…

EZH2 (enhancer of zeste homolog 2) is the catalytic subunit of PRC2 (polycomb repressive
complex 2), which mediates histone methyltransferase activity and functions as …

Purpose: We evaluated plasma cell-free DNA (cfDNA) and tissue-based sequencing
concordance for comprehensive oncogenic driver detection in non–small cell lung cancer (NSCLC) …

Objectives Several preclinical data proposed a potential efficacy of osimertinib, a third-generation
EGFR tyrosine kinase inhibitor, for EGFR exon 20 insertion (EGFR ex20ins)-positive …

Recent discoveries have revealed that human cancer involves aberrant epigenetic alterations.
We and others have previously shown that the histone methyltransferase EZH 2, the …

Delta‐like protein 3 ( DLL 3) is a ligand of Notch signaling, which mediates cell‐fate decisions
and is tumor‐suppressive or oncogenic depending on the cellular context. Previous …

Background Delta‐like protein 3 (DLL3) is a Notch ligand that has an important role in the
tumorigenesis of small cell lung cancer (SCLC). Recently, rovalpituzumab tesirine (Rova‐T), a …

Osimertinib is a third‐generation epidermal growth factor receptor (EGFR)‐tyrosine kinase
inhibitor (TKI) that has shown marked antitumor activity in patients with EGFR‐mutated non–…

Background CD133 is a membrane glycoprotein containing five transmembrane loops. Previous
reports suggest that a CD133-positive subpopulation of multipotent cells with extensive …

Background and Aim Immune checkpoint inhibitors (ICI) have revolutionized anti‐malignancy
therapy and thus have been increasingly used. Although ICI may cause immune‐related …